Background/Objectives:Bladder cancer is characterized by high recurrence and progression rates, posing a challenge to current diagnostic and treatment strategies. This review aims to provide a comprehensive overview of emerging technologies, including novel PET tracers, AI-assisted cystoscopy, theragnostics, and molecular biomarkers.Methods: We performed a narrative review of the recent literature focusing on innovations in imaging, AI, theragnostics, and biomarker research relevant to bladder cancer diagnosis and management.Results: Several novel PET tracers, such as 68Ga-PSMA and fibroblast activation protein inhibitor (FAPI), demonstrated potential in improving detection sensitivity. AI-enhanced cystoscopy has shown promise in real-time lesion detection, while theragnostic agents enable combined diagnostic and therapeutic applications. Advances in molecular biomarkers, including circulating Tumor DNA (ctDNA) and gene expression signatures, offer new avenues for patient stratification and monitoring.Conclusions: Integration of advanced imaging, AI, theragnostics, and biomarker analysis may transform bladder cancer management, supporting personalized and more effective care strategies.
**背景/目的：** 膀胱癌具有高复发率和高进展率的特点，对现有诊疗策略构成挑战。本综述旨在全面概述新兴技术，包括新型PET示踪剂、AI辅助膀胱镜、诊疗一体化技术及分子生物标志物。 **方法：** 我们对近期文献进行了叙述性综述，重点关注与膀胱癌诊断和管理相关的影像学、人工智能、诊疗一体化及生物标志物研究领域的创新进展。 **结果：** 多种新型PET示踪剂（如⁶⁸Ga-PSMA和成纤维细胞活化蛋白抑制剂[FAPI]）显示出提高检测敏感性的潜力。AI增强膀胱镜在实时病变检测中表现出应用前景，而诊疗一体化试剂实现了诊断与治疗的结合应用。分子生物标志物（包括循环肿瘤DNA[ctDNA]和基因表达特征谱）的进展为患者分层和监测提供了新途径。 **结论：** 整合先进影像技术、人工智能、诊疗一体化及生物标志物分析，有望革新膀胱癌的临床管理，推动个性化及更高效诊疗策略的发展。
肿瘤(癌症)患者之家